$FOXO

FOXO TECHNOLOGIES INC.

FOXO Technologies is a healthcare services and technology company headquartered in West Palm Beach, Florida. It operates three reportable segments: Healthcare, Life Science Services and Labs. Healthcare includes Myrtle Recovery Centers, which provides inpatient, residential and outpatient behavioral health services, primarily for substance use disorders, and Scott County Community Health, doing business as Big South Fork Medical Center, a 25-bed critical access hospital in Oneida, Tennessee. The hospital has a 24/7 emergency department and offers laboratory, radiology, respiratory and pharmacy services. Life Science Services provider Vector BioSource sources and distributes biological materials and provides data services for biotechnology, clinical research and pharmaceutical research. FOXO makes money from healthcare services and biospecimen sourcing, distribution and data services. Its Labs segment is commercializing saliva-based epigenetic biomarker technology for life insurance underwriting and risk assessment, alongside bioinformatics tools and epigenetic testing services for researchers.

1
0
0

No SEC Form 4 filings for $FOXO in the last 30 days.

See all $FOXO insider activity →
Med

FOXO Technologies 3Q 2026: Revenue $7M — 10-Q Summary

FOXO Technologies reported 3Q 2026 revenue of $7M, up 97.38% YoY, with earnings shifting from a loss to income. Growth was driven by higher RCHI revenue, including Medicare adjustments and rate changes. The Life Science Services segment saw revenue increase to $406,953. The Grifols acquisition remains pending regulatory approvals and financing.

FOXO TECHNOLOGIES INC. (FOXO): Entry into a Material Definitive Agreement

FOXO TECHNOLOGIES INC. (FOXO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 FOXO TECHNOLOGIES INC. ANNOUNCES AGREEMENTS TO ACQUIRE PREFERRED STOCK CARRYING MAJORITY VOTING POWER IN LUDWIG ENTERPRISES, INC. WEST PALM BEACH, FL, October 29, 2026 (GLOBE NEWSWIRE) — FOXO Technologies Inc . (OTC: FOXO) (“FOXO” or the “Company”) today announced th

A Tennessee recovery center now serves patients with medical needs as well as addiction needs

FOXO Technologies Inc. (OTC: FOXO) announced that its subsidiary, Myrtle Recovery Centers, received a license to expand its Tennessee facility by 2 beds, increasing capacity to 32. The facility now also serves patients with medical needs alongside addiction treatment. Since 2023, Myrtle has treated over 1,300 patients. FOXO's CEO noted the expansion creates additional revenue opportunities.

FOXO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning FOXO (FOXO TECHNOLOGIES INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent FOXO coverage spans financial news, corporate actions and earnings.

What's driving FOXO

  • Improving revenue and operating income suggests near-term fundamental support, but the still-unclosed Grifols four-center acquisition adds execution and regulatory uncertainty.

    tradingview.com · Nov 16, 2026

  • Potential dilution and voting control shift if the acquisition closes; price may rise on acquisition news but depends on Nasdaq listing success.

    SEC EDGAR 8-K · Oct 29, 2026

  • The license expansion modestly increases Myrtle's capacity, likely supporting incremental revenue growth for FOXO.

    stocktitan.net · Oct 19, 2026

  • The filing signals a capital-markets and listing-readiness move that can affect liquidity, per-share pricing, and near-term trading dynamics.

    SEC EDGAR 8-K · Aug 14, 2026

  • The filing signals FOXO is party to a material asset acquisition agreement, but the excerpt provides no purchase price, closing terms, or deal economics.

    SEC EDGAR 8-K · Jul 27, 2026

AlphAI scores every news story that mentions FOXO with an AI model for sentiment and relevance, and aggregates insider trades from FOXO TECHNOLOGIES INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $FOXO

Score

FOXO Technologies 3Q 2026: Revenue $7M — 10-Q Summary

FOXO Technologies reported 3Q 2026 revenue of $7M, up 97.38% YoY, with earnings shifting from a loss to income. Growth was driven by higher RCHI revenue, including Medicare adjustments and rate changes. The Life Science Services segment saw revenue increase to $406,953. The Grifols acquisition remains pending regulatory approvals and financing.

$FOXOMedM&A· acquirer · announced

FOXO TECHNOLOGIES INC. (FOXO): Entry into a Material Definitive Agreement

FOXO TECHNOLOGIES INC. (FOXO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 FOXO TECHNOLOGIES INC. ANNOUNCES AGREEMENTS TO ACQUIRE PREFERRED STOCK CARRYING MAJORITY VOTING POWER IN LUDWIG ENTERPRISES, INC. WEST PALM BEACH, FL, October 29, 2026 (GLOBE NEWSWIRE) — FOXO Technologies Inc . (OTC: FOXO) (“FOXO” or the “Company”) today announced th

A Tennessee recovery center now serves patients with medical needs as well as addiction needs

FOXO Technologies Inc. (OTC: FOXO) announced that its subsidiary, Myrtle Recovery Centers, received a license to expand its Tennessee facility by 2 beds, increasing capacity to 32. The facility now also serves patients with medical needs alongside addiction treatment. Since 2023, Myrtle has treated over 1,300 patients. FOXO's CEO noted the expansion creates additional revenue opportunities.

$FOXOMedShareholder vote

FOXO TECHNOLOGIES INC. (FOXO): Submission of Matters to a Vote of Security Holders

FOXO TECHNOLOGIES INC. (FOXO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 13, 2026, Rennova Health, Inc. (which is controlled by the Company’s CEO) (the “ Majority Stockholder ”), a shareholder representing a majority of the voting control of the Company, approved certain actions

$FOXOMedM&A· acquirer · $3.5M · definitive

FOXO TECHNOLOGIES INC. (FOXO): Entry into a Material Definitive Agreement

FOXO TECHNOLOGIES INC. (FOXO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 Execution version Strictly Private and Confidential Certain schedules and exhibits to this Asset Purchase Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby agrees to furnish supplementally a copy

Related tickers